Gunnar Esiason is a cystic fibrosis and rare disease patient leader, who is passionate about early-stage drug development, patient empowerment and health policy. He has consulted with healthcare venture investors, assisted on clinical trial design, and has been the face of fundraising efforts for the Boomer Esiason Foundation, which has yielded more than $160 million for the fight against cystic fibrosis. During the coronavirus pandemic, Gunnar was a leading voice for equitable vaccine access for people with underlying health conditions. His editorials have been published in USA Today, the Wall Street Journal, The Hill and STAT News. Gunnar holds an M.B.A. from the Tuck School of Business at Dartmouth.